Table 1. Retinoblastoma cell lines and associated patient characteristics

Cell line	Laterality	Male / Female	Age at diag (months)	RB1 mutations ¹	MYCN Amplification
BCH-RB31	bilateral	F	19	c.1039dupT (blood)	Y
BCH-RB32	unilateral	F	22	46,XX,del(13)(q12q14) (blood)	N
BCH-RB33	bilateral	Μ	20	46,XY,del(13)(q14.1q14.2) (blood)	N
BCH-RB34	unilateral	М	26	None found in tumour	N
BCH-RB35	unilateral	F	26	None found in tumour ²	N
BCH-RB36	unilateral	М	31	c.751C>T p.(Arg251Ter), c.1363C>t p.(Arg455Ter)	N
BCH-RB37	unilateral	М	25	c.184C>T p.(Gln62Ter), LOH	N
BCH-RB38	unilateral	М	15	c.1961-1G>T, RB1 whole gene deletion	N
BCH-RB39	unilateral	Μ	32	c.1060-1061delCA, LOH	N
BCH-RB40	unilateral	М	32	Hypermethylation of RB1 promoter	N
BCH-RB41	unilateral	F	21	n.d.	N
BCH-RB42	unilateral	М	14	Whole gene deletion, c.1383C>T p.(Arg455Ter)	Y
BCH-RB43	unilateral	Μ	52	Tumour whole gene deletion (homozygous)	N
BCH-RB44	unilateral	М	10	Whole gene deletion	N
BCH-RB45	bilateral	F	3	c.958 C>T p.(Arg320Ter) (blood)	N
BCH-RB46	bilateral	F	26	Deletion exon 24 to 27 (blood)	N
BCH-RB47	bilateral	F	23	Whole gene deletion	N
BCH-RB49	unilateral	F	28	c.1399C>T p.(Arg467Ter) blood), LOH	N
BCH-RB50	unilateral	Μ	18	Whole gene deletion	N
BCH-RB51	unilateral	F	15	c.2520+1G>C (mosaic), c.2053C>T p.(Gln685Ter)	N
BCH-RB52	unilateral	F	5	c.380+1G>A, c.2359C>T p.(Arg787Ter)	N
BCH-RB53	bilateral	F	34	c.763C>T p.(Arg255Ter)	N
BCH-RB54	unilateral	F	45	c.1251_1252delAA, LOH	N
BCH-RB55	unilateral	F	27	c.1363C>T p.(Arg455Ter), LOH	N
BCH-RB56	Unilateral	М	29	c.1454_1457 del CTTT p.(Ser458Tyrfster9), LOH	N
BCH-RB57	unilateral	М	n.r.	c.1363C>T p.(Arg455Ter) mosaic in blood	N
BCH-RB58	unilateral	F	n.r.	n.d.	N
BCH-RB59	bilateral	М	n.r.	13q-	N

¹Mutations taken from clinical reports. ²Clinical report: no mutation found; this study (RNA-seq) found a chr13 rearrangment RB1-RCBTB2. n.r. : not recorded.

Table 2 BGGR mutations in metinoblastoma cell lines

Cell line	Male/ female	Method ¹	% Mutation positive reads	Exon	cDNA NM_001123383.1	gDNA NG_008880.1	Protein (predicted) NP_001116855.1	LCL /Str ²	Validation 2nd cell line ³	Validation Tumour ⁴
RB31	F	SS		13-14	c.5003_5237del	g. [127955_127957del;127961 _128713del]	p.Asp1547Glyfs*15	wt	Y	Y
RB32	F	SS		4	c.1285C>T	g.107906C>T	p.Gln308*	wt	n.d.	Y^
RB33	М	RNA-seq	n.a.	-	None found	-	-	-	-	-
RB34	М	SS		1-15	c.(?_299)_(5536_?)del	g.(?_4909)_(130376_?)del	p.1_1721del	wt	Y	n.d.
RB35	F	RNA-seq		4-6	c.3601_3602ins[NC_0 00007.14:145323333_ 145323371; 1010_3601]	g. (111358_1117730)ins[NC_00 0007.14: g.?_145323371;107631_(11 1358_1117730)]	p.Cys1080*	wt	n.d.	Y
RB36	М	SS		9-10	c.4109_4689del	9del g.119363_120216del p.Leu1250Serfs*1		wt	Y	Υ^
RB37	М	RNA-seq	93	8	c.3970dupG	3970dupG g.118584dupG p.Val1203Glyfs*8 wt		n.d.	Y^	
RB38	М	RNA-seq	100	4	c.2687T>A	g.109308T>A	p.Leu775*	wt	Y	N
RB39	М	SS		7	c.3703G>T	'03G>T g.117832G>T p.Glu1114* wt		Y	n.d.	
RB40	М	RNA-seq	n.a.	-	None found	None found	-			-
RB41	F	SS		-	None found	None found	-	-	-	-
RB42	М	SS		-	None found	None found	-	-		-
RB43	М	M RNA-seq 1-15 c.1_6390del g.(?_4909)_(130376_?)del No protein wt		Y	n.d.					
RB44	М	SS		2-5	no expression	g.(98055_98478)_(110641_1 10766)del	(p.1_1017del)	wt	No 2nd line	No tissue
RB45	F	RNA-seq	n.a.	-	None found	None found	-	-	-	-
RB46	F	RNA-seq	37	7	c.3744_3765del	g.117873_117894del	p.Ser1127Argfs*25	wt	No 2nd line	N
RB47	F	SS		2,3,partial 4	c.[324_2837del; 324_2754delins[NG_0 08880.1:g62491_6296 8]]	g.[(5314_?)_(?_62491)del;62 969_109375del]	p.?	wt	Y	No tissue
RB49	F	SS		-	None found ⁵	None found ⁵	-	-	-	-
RB50	М	SS		7	c.3703delG	g.117832delG	p.Glu1114Serfs*45	no cells	n.d.	Y

Variants are reported relative to the reference sequence LRG_627(BCOR): genomic sequence source: NG_008880.1; transcript LRG_627t1 sequence source: NM_001123383.1, initiation codon at position 364; protein sequence source: NP_001116855.1. ¹SS: Sanger sequencing. ²Genotype of lymphoblastoid cell line or ocular stromal cells: wt: wild type; ³Mutation present in both cell lines established from the original tumour: Y: yes, n.d.: not done. ⁴ Cell line mutation present in tumour: Y: yes, N: no, [^]both mutant and wildtype sequence present; ⁵RB49 showed significantly reduced BCOR expression (Figure 2), but no mutation was detected.

 Table 3. GO categories associated with altered gene expression in BCOR-mutated retinoblastoma cell lines

Table 2. GO categories a	associated with altered gene	expression in BCOR-mutated	retinoblastoma cell lines
--------------------------	------------------------------	----------------------------	---------------------------

DOWN-REGULATED GEN	ES		
Annotation Cluster	Enrichment Secre	Fold	D volue
Annotation Cluster	Emichment Score	Enrichment	r value
Category	Term		
Annotation Cluster 1	Enrichment Score: 10.01		
GOTERM_BP_FAT	GO:0050953~sensory perception of light stimulus	6.48	6.95E-14
GOTERM_BP_FAT	GO:0007601~visual perception	6.48	6.95E-14
GOTERM_BP_FAT	GO:0007600~sensory perception	2.05	1.92E-04
Annotation Cluster 2	Enrichment Score: 3.54		
GOTERM_CC_FAT	GO:0000267~cell fraction	1.91	1.93E-04
GOTERM_CC_FAT	GO:0005624~membrane fraction	2.07	2.52E-04
GOTERM_CC_FAT	GO:0005626~insoluble fraction	2	4.60E-04
Annotation Cluster 3	Enrichment Score: 3.40		
GOTERM_BP_FAT	GO:0009583~detection of light stimulus	10.63	8.12E-06
GOTERM_BP_FAT	GO:0007602~phototransduction	10.99	3.41E-05
GOTERM_BP_FAT	GO:0009581~detection of external stimulus	6.3	8.42E-05
GOTERM_BP_FAT	GO:0009582~detection of abiotic stimulus	6.38	2.40E-04
GOTERM_BP_FAT	GO:0009416~response to light stimulus	3	1.72E-02
GOTERM_BP_FAT	GO:0009314~response to radiation	2.33	3.96E-02
Annotation Cluster 4	Enrichment Score: 2.38		
GOTERM_BP_FAT	GO:0032496~response to lipopolysaccharide	5.39	6.83E-04
GOTERM_BP_FAT	GO:0002237~response to molecule of bacterial origin	4.82	1.32E-03
GOTERM_BP_FAT	GO:0009617~response to bacterium	2.15	7.92E-02
Annotation Cluster 5	Enrichment Score: 2.10		
GOTERM_MF_FAT	GO:0010853~cyclase activator activity	23.48	6.51E-03
GOTERM_MF_FAT	GO:0030250~guanylate cyclase activator activity	23.48	6.51E-03
GOTERM_MF_FAT	GO:0030249~guanylate cyclase regulator activity	20.54	8.57E-03
GOTERM MF FAT	GO:0010851~cyclase regulator activity	18.26	1.09E-02

UP-REGULATED GENES

Annotation Cluster	Enrichment Score	Fold	P value
		Enrichment	i value
Category	Term		
Annotation Cluster 1	Enrichment Score: 6.76		
GOTERM_BP_FAT	GO:0007409~axonogenesis	5.74	5.32E-09
GOTERM_BP_FAT	GO:0048812~neuron projection morphogenesis	5.2	2.51E-08
GOTERM_BP_FAT	GO:0048858~cell projection morphogenesis	4.76	4.06E-08
GOTERM_BP_FAT	GO:0032990~cell part morphogenesis	4.56	8.20E-08
GOTERM_BP_FAT	GO:0048666~neuron development	3.96	8.26E-08
GOTERM_BP_FAT	GO:0031175~neuron projection development	4.33	4.07E-07
GOTERM_BP_FAT	GO:0030030~cell projection organization	3.49	1.36E-06
GOTERM_BP_FAT	GO:0000902~cell morphogenesis	3.44	3.13E-06
GOTERM_BP_FAT	GO:0032989~cellular component morphogenesis	3.08	1.58E-05
Annotation Cluster 2	Enrichment Score: 5.79		
GOTERM_MF_FAT	GO:0022836~gated channel activity	4.19	6.31E-08
GOTERM_MF_FAT	GO:0005216~ion channel activity	3.52	6.12E-07
GOTERM_MF_FAT	GO:0022838~substrate specific channel activity	3.41	1.02E-06
GOTERM_MF_FAT	GO:0015267~channel activity	3.29	1.81E-06
GOTERM_MF_FAT	GO:0022803~passive transmembrane transporter activity	3.29	1.89E-06

Table 4. Genes associated with specific retinal lineages that are upregulated in BCOR mutated retinoblastoma cell lines.

Table 3. Genes associated with specific retinal lineages that are upregulated in BCOR mutated retinoblastoma cell lin

Gene	Fold Change	BaseMean ¹	Cell Types ²
BARHL2	24.3	288	Amacrine, Ganglion
BHLHE22	31.3	1740	Amacrine, Bipolar
EBF3	6.6	14258	Ganglion, Amacrine, Bipolar
NEUROD2	92.5	624	Ganglion, Amacrine
NOTCH1	8.9	3616	Retinal progenitor cells
ONECUT1	9.6	2260	Horizontal, cone
POU4F2	4.6	1707	Ganglion
SALL3	11.2	966	Horizontal, Cone,
SATB1	12.6	2997	Ganglion
SATB2	8.9	1349	Amacrine, Ganglion

¹BaseMean is the the average of the normalized read counts taken over all samples (log normalized scale) and provides an indication of the overall level of expression of each gene (GAPDH BaseMean: 232817 Fold change: 1.03). ²Retinal cell type markers are as reported⁷⁰⁻⁷⁴



Figure 1. BCOR functional domains and BCOR mutations in RB cell lines. Red lines: deletions; Green lines: inserted sequence. Red triangles: small sequence alterations. Dark blue lines: aberrant splicing. Two transcripts were identified for RB47: in one, exon 1A was spliced to an internal position (c.2838) in exon 4; in the second, exon 1A was spliced to a segment of intron 1A which was joined to an internal position (c.2755) in exon 4 as a genomic rearrangement. The RB35 cell line showed a genomic rearrangement between an intergenic segment of chromosome 7q35 and BCOR exon 4.

RB46 - Deletion (22bp) Exon 7 (direct & inverted repeats) AGACCAGGTGGCCTCGGACATGCCTCACGCCCCCCCGGCTGGACAGCAAGCA
RB55 - Deletion (19bp) Exon 8 (direct and inverted repeats)
AAACAACGCCACTTGCTGCACCTTAGAGAACGATGGGA <mark>GCAGCA</mark> GGTGTCG <mark>GCAGCAG</mark> ATGGCAAACCTGGCCGGCAAAG NG_008880 Exon 8
RB31 - Deletion (759bp) exons 13 & 14 (slippage and inverted repeat; mirror repeat) TGCCACGTGGCTCTGCCATCATTTTGTTCTCAGCAGTAGATTTTATCTTTGTTTTTTTT
RB35 - Chr7-BCOR Rearrangement (4 base homology, <u>direct repeat</u> , <u>mirror repeat</u>)
ATGAAAATACAAGAGAATGATTAAATTTTTTTAACATTTAACATTTAAAAACAAGTCAAGAATGTG Chr7 IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
RB44 - Deletion Exons 2 - 5 The deletion boundaries were mapped to within 444bp and 125bp of 5' and 3' breakpoints respectively but it was not possible to amplify a junction fragment. This may be a complex insertion/deletion event
RB47 - Deletion (46kb)Exons 2, 3 & partial 4 (inverted/direct repeat) CCATCCTGACTTATAACAACTCAGATTAAAACCTTTGCCCACTTTAAAACTTGACATAGG NG_008880 Intron 1A IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
RB36 - Deletion (853bp) Exons 9 & 10 (interrupted homology; G-rich sequence) CAGCCAAGCTGCGCACCAGCCTCCCAGGCGCCCAGCCAAGCAGAAAATTAAAGAAAACC NG_008880 Exon 9 IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
RB57 - Deletion (62kb) Exons 1B - 10 (2 direct repeats & inverted repeat) TCTGATGTGGCCAAAGCTTCCTATGGTATGGTATGCAAGCAGTCCCGCCGTCAGG NG_008880 Intron 1A IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
Figure 2. Sequence context of BCOR intragenic break-points.



Figure 3. Protein interaction network around the hub proteins Notch1, FYN and KIT. Proteins are encoded by genes that are either upregulated (green nodes) or downregulated (blue nodes) in BCOR-mutated cell lines.



Figure 4. RB45. Focus of BCOR-negative retinoblastoma cells in the choroid (*)



Figure 5. RB42, moderately differentiated with both BCOR-positive and negative regions and corresponding differentiated/undifferentiated histopathology respectively. A. Differentiated (blue box) and undifferentiated (red box) RB with optic nerve invasion (ONI).
B. FW rosettes in the anterior tumour show strong BCOR positivity. C, D. Undifferentiated RB, with low level BCOR staining, adjacent to and invading the post-laminar optic nerve.



Figure 6. Retinoblastomas RB49 and RB33 are mostly BCOR-negative, but contain BCOR-positive tumour cells within the inner nuclear layer and the subretinal region (A, B: BCH-49; C, D: BCH-33).



